

BIOMEDICAL STARTUP RECEIVES FUNDING SUPPORT FOR IMPORTANT MEDICAL RESEARCH

ABOUT THERAGNOSTIC TECHNOLOGIES (BALAJI SITHARAMAN).

Theragnostic Technologies is a seed-stage biomedical company that offers a range of cutting-edge biomedical and healthcare products to improve imaging, therapy and tissue regeneration. A StartUp NY participant, Theragnostic Technologies is located in the Long Island High Technology Incubator at Stony Brook University. The company aims to be a leader in providing innovative solutions that advance healthcare and improve quality of life, providing materials, tools and methods at the interface of nanotechnology and biomedical science and engineering.

THE CHALLENGE. Theragnostic Technologies is conducting research on an investigational new drug (IND) that will be used to diagnose and monitor patients with renal or kidney failure. Many diseases or health problems can lead to acute kidney injury or chronic kidney disease, which is when the kidney fails to filter toxins and waste products from the blood. Every year in the U.S., 0.6 million individuals are diagnosed with an acute kidney injury, and over 20 million people have chronic kidney disease. These acute and chronic illnesses result in morbidity, mortality, and an increased burden on health care resources and costs. Theragnostic Technologies is researching applications for a novel high performance carbon nanostructure-based magnetic resonance imaging (MRI) contrast agent (CA) to help detect and manage this health issue.

MEP CENTER'S ROLE. The Small Business Innovation Research (SBIR) program, developed by the National Institutes of Health (NIH), funds early stage small businesses seeking to commercialize innovative biomedical technologies. Theragnostic Technologies received an NIH SBIR Phase I and II award for its IND research, and the Manufacturing & Technology Resource Consortium (MTRC), part of the MEP National Network, is supporting the company with a supplemental award.

MTRC is also working with Theragnostic Technologies through the many phases of developing this drug. The company is hiring additional staff and testing the sustainability of the product through preclinical efficacy and safety evaluations. Support from SBIR and MTRC will enable Theragnostic Technologies to bring its product to market, increasing its competitiveness in the medical field and providing assistance to the millions of patients suffering from renal or kidney failure.

RESULTS



Obtained SBIR awards



Used funding support to invest in retaining positions



Product testing will increase competitiveness

CONTACT US



625 Broadway
ESD, Division of Science,
Technology & Innovation
(NYSTAR)
Albany, NY 12245



(518)292-5729



www.esd.ny.gov/nystar/nymep.asp



NEW YORK
Manufacturing
Extension Partnership